A US NDA for the Company's lead product, DURLAZA™,
was submitted to the FDA in early September 2014,
with approval and US launch expected in Q3 2015.

Anti-platelet Therapy Products

DURLAZA™ - A novel anti-platelet therapy combining proprietary API
with proprietary drug delivery technology.
DURLAZA was developed in consultation with a Nobel laureate specifically to provide 24 hour anti-platelet coverage
and will be indicated for patients at risk of a secondary
stroke or acute cardiac event.

DURLAZA with Zinc Salts - A second generation combination product currently in development (successor to DURLAZA™) incorporating proprietary Yale University zinc salts technology that is expected to provide added patient benefit.